News

Filter

Current filters:

Velcade

1 to 9 of 157 results

European Commission approves added indication for Janssen’s Velcade, in MCL

European Commission approves added indication for Janssen’s Velcade, in MCL

06-02-2015

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen-Cilag International NV (Janssen)…

BiotechnologyEuropeJanssen-Cilag InternationalJohnson & JohnsonOncologyRegulationVelcade

EHA 2014: Velcade combination shows high efficacy in Mantle Cell Lymphoma

EHA 2014: Velcade combination shows high efficacy in Mantle Cell Lymphoma

16-06-2014

Janssen-Cilag International, a subsidiary of US health care giant Johnson & Johnson, announced Phase…

EuropeHematologyJanssen-CilagLymphomaPharmaceuticalResearchVelcade

Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

10-06-2014

Certain targeted therapies enjoy extensive but incomplete coverage in Brazil and Mexico through complex…

BiosimilarsBrazilJohnson & JohnsonMabTheraMexicoOncologyPharmaceuticalPricingRocheVelcade

ASCO 2014: Takeda, Roche and Celgene present results

ASCO 2014: Takeda, Roche and Celgene present results

02-06-2014

A host of results have been presented by global pharma majors at the 2014 Annual Meeting of the American…

AbraxaneCelgeneOncologyPharmaceuticalResearchRocheTakeda PharmaceuticalsUSAVelcade

UK NICE backs Janssen’s Velcade for multiple myeloma

UK NICE backs Janssen’s Velcade for multiple myeloma

21-03-2014

In new draft guidance published today, UK drugs watchdog the National Institute for Health and Care Excellence…

JanssenJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

1 to 9 of 157 results

COMPANY SPOTLIGHT

Menarini

Back to top